Detalhe da pesquisa
1.
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Gynecol Oncol
; 146(3): 484-490, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28698009
2.
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood
; 119(20): 4614-8, 2012 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-22422826
3.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Cancer Cell
; 10(1): 39-50, 2006 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-16843264
4.
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Blood
; 115(17): 3520-30, 2010 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-20197554
5.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
J Immunol
; 184(9): 5298-307, 2010 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20363976
6.
Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.
Bioorg Med Chem Lett
; 21(6): 1827-31, 2011 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21316220
7.
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Cancer Discov
; 11(2): 326-339, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33218975
8.
Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.
Biochem Biophys Res Commun
; 387(2): 251-5, 2009 Sep 18.
Artigo
Inglês
| MEDLINE | ID: mdl-19576173
9.
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
J Immunother Cancer
; 7(1): 80, 2019 03 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30894212
10.
Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Bioorg Med Chem Lett
; 18(6): 1958-62, 2008 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18282708
11.
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
Bioorg Med Chem Lett
; 18(5): 1577-82, 2008 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18242982
12.
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Bioorg Med Chem Lett
; 18(4): 1288-92, 2008 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18234496
13.
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Bioorg Med Chem Lett
; 18(2): 694-9, 2008 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18061445
14.
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
Bioorg Med Chem Lett
; 18(1): 241-6, 2008 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18032037
15.
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.
Clin Cancer Res
; 13(6): 1892-902, 2007 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17363546
16.
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Clin Cancer Res
; 23(13): 3269-3276, 2017 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28053021
17.
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
Cancer Biol Ther
; 5(6): 648-56, 2006 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-16627988
18.
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
J Med Chem
; 48(6): 2194-211, 2005 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-15771462
19.
Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).
Matrix Biol
; 21(6): 499-511, 2002 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-12392761
20.
Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
J Med Chem
; 47(12): 2981-3, 2004 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-15163180